Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMD9N12)

Drug Name

BAY 2416964 Drug Info

Synonyms

2242464-44-2; BAY2416964; SCHEMBL20471217; BCP33103; EX-A4271; MFCD32693912; NSC825713; s8995; NSC-825713; BAY-2416964; HY-135829; CS-0114330; BAY-2416964;BAY2416964; ClC1=CC=C(C=C1)C=1C=C(C(N(N=1)C=1C=NN(C=1)C)=O)C(=O)N[C@H](CO)C; (S)-6-(4-Chlorophenyl)-N-(1-hydroxypropan-2-yl)-2-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydropyridazine-4-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

PubChem CID: 135303769
TTD Drug ID: DMD9N12

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Preclinical Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Aryl hydrocarbon receptor (AHR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[2]
Tapinarof	DMRPI2Q	Plaque psoriasis	EA90.0	Approved	[3]
RVT-505	DM3C9F8	Atopic dermatitis	EA80	Phase 2	[4]
IK-175	DMDU54Y	Urothelial carcinoma	2C92.0	Phase 1	[5]
AT-177	DMJ02RH	Ulcerative colitis	DD71	Clinical trial	[6]
CB7993113	DMJUQ6E	Solid tumour/cancer	2A00-2F9Z	Preclinical	[7]
2-(1H-indole-3,-carbonyl)-thiazole-4-carboxylic acid methyl ester	DMIS1G7	Glioma	2A00.0	Preclinical	[8]
6-Formylindolo[3,2-b]carbazole	DMN84RM	Dermatitis	EA80-EA89	Investigative	[9]
CH-223191	DMMJZYC	Solid tumour/cancer	2A00-2F9Z	Investigative	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aryl hydrocarbon receptor (AHR)	TT037IE	AHR_HUMAN	Antagonist	[1]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04069026) A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer. U.S. National Institutes of Health.
2	A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer. 2005 Oct 17;93(8):876-83.
3	FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 215272.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Clinical pipeline report, company report or official report of Ikena Oncology.
6	Clinical pipeline report, company report or official report of Azora Therapeutics
7	In silico identification of an aryl hydrocarbon receptor antagonist with biological activity in vitro and in vivo. Mol Pharmacol. 2014 Nov;86(5):593-608.
8	1'H-Indole-3'-Carbonyl-Thiazole-4-Carboxylic Acid Methyl Ester Blocked Human Glioma Cell Invasion via Aryl Hydrocarbon Receptor's Regulation of Cytoskeletal Contraction. Biomed Res Int. 2020 Oct 3;2020:2616930.
9	6-Formylindolo(3,2-b)carbazole induced aryl hydrocarbon receptor activation prevents intestinal barrier dysfunction through regulation of claudin-2 expression. Chem Biol Interact. 2018 May 25;288:83-90.
10	Novel compound 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) prevents 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor. Mol Pharmacol. 2006 Jun;69(6):1871-8.